Introduction: Efficacy of tildrakizumab (TIL), a high-affinity, humanized, IgG1/κ monoclonal antibody against IL-23p19, has been evaluated for chronic plaque psoriasis (Pso) in 2 phase 3 randomized controlled trials. The objective of this analysis was to determine predictors of response to TIL treatment in the 2 trials.
Παρασκευή 10 Αυγούστου 2018
Predictors of response to tildrakizumab for moderate-to-severe chronic plaque psoriasis
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Publication date: Available online 28 September 2017 Source: Actas Dermo-Sifiliográficas Author(s): F.J. Navarro-Triviño
-
Abstract Objectives To investigate factors related to reasoning skills in 434 school children aged 5–9 years. Methods The Leiter Interna...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.